BR112012019374B1 - Composição farmacêutica oral e uso de um agente ativo para a preparação de uma composição farmacêutica oral para o tratamento de doenças neurodegenerativas - Google Patents
Composição farmacêutica oral e uso de um agente ativo para a preparação de uma composição farmacêutica oral para o tratamento de doenças neurodegenerativas Download PDFInfo
- Publication number
- BR112012019374B1 BR112012019374B1 BR112012019374-0A BR112012019374A BR112012019374B1 BR 112012019374 B1 BR112012019374 B1 BR 112012019374B1 BR 112012019374 A BR112012019374 A BR 112012019374A BR 112012019374 B1 BR112012019374 B1 BR 112012019374B1
- Authority
- BR
- Brazil
- Prior art keywords
- weight
- layer
- pharmaceutical composition
- entire
- salt
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 75
- 238000011282 treatment Methods 0.000 title claims abstract description 31
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 19
- 239000008203 oral pharmaceutical composition Substances 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title description 18
- 239000008188 pellet Substances 0.000 claims abstract description 127
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims abstract description 98
- 229960000245 rasagiline Drugs 0.000 claims abstract description 87
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 49
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 35
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 239000012730 sustained-release form Substances 0.000 claims abstract description 30
- 238000013268 sustained release Methods 0.000 claims abstract description 28
- 230000006378 damage Effects 0.000 claims abstract description 19
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 19
- 210000000653 nervous system Anatomy 0.000 claims abstract description 11
- 238000013265 extended release Methods 0.000 claims description 127
- 239000010410 layer Substances 0.000 claims description 93
- 229940079593 drug Drugs 0.000 claims description 92
- 239000003814 drug Substances 0.000 claims description 92
- 229920000642 polymer Polymers 0.000 claims description 73
- 238000000576 coating method Methods 0.000 claims description 39
- 239000000314 lubricant Substances 0.000 claims description 39
- 239000011248 coating agent Substances 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 30
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 30
- 239000011247 coating layer Substances 0.000 claims description 29
- 239000011230 binding agent Substances 0.000 claims description 25
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 24
- 238000004090 dissolution Methods 0.000 claims description 23
- -1 poly(propylene glycols) Polymers 0.000 claims description 23
- 239000000454 talc Substances 0.000 claims description 21
- 229910052623 talc Inorganic materials 0.000 claims description 21
- 229920001223 polyethylene glycol Polymers 0.000 claims description 17
- 229940033134 talc Drugs 0.000 claims description 17
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 16
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 16
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 16
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 15
- 230000001419 dependent effect Effects 0.000 claims description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims description 14
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 13
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 10
- 239000001856 Ethyl cellulose Substances 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 10
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 10
- 229920001249 ethyl cellulose Polymers 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000004014 plasticizer Substances 0.000 claims description 10
- 230000002035 prolonged effect Effects 0.000 claims description 10
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 9
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 9
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 230000001681 protective effect Effects 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 229920001688 coating polymer Polymers 0.000 claims description 6
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 6
- 239000002702 enteric coating Substances 0.000 claims description 6
- 238000009505 enteric coating Methods 0.000 claims description 6
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 6
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 5
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- TYVWBCMQECJNSK-UHFFFAOYSA-N [2-methyl-3-(2-methylprop-2-enoyloxy)butan-2-yl]azanium;chloride Chemical compound [Cl-].CC([NH3+])(C)C(C)OC(=O)C(C)=C TYVWBCMQECJNSK-UHFFFAOYSA-N 0.000 claims description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 4
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical class CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 4
- 229960004063 propylene glycol Drugs 0.000 claims description 4
- 235000013772 propylene glycol Nutrition 0.000 claims description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 3
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical group CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical group CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 3
- 159000000021 acetate salts Chemical class 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims description 3
- 208000029028 brain injury Diseases 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000001087 glyceryl triacetate Substances 0.000 claims description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 150000008054 sulfonate salts Chemical class 0.000 claims description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 3
- 150000003892 tartrate salts Chemical class 0.000 claims description 3
- 125000005490 tosylate group Chemical class 0.000 claims description 3
- 229960002622 triacetin Drugs 0.000 claims description 3
- 239000001069 triethyl citrate Substances 0.000 claims description 3
- 235000013769 triethyl citrate Nutrition 0.000 claims description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 230000006931 brain damage Effects 0.000 claims description 2
- 231100000874 brain damage Toxicity 0.000 claims description 2
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 2
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 claims description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims 1
- 229920000578 graft copolymer Polymers 0.000 claims 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 238000009498 subcoating Methods 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 25
- 238000009472 formulation Methods 0.000 abstract description 19
- 150000001875 compounds Chemical class 0.000 abstract description 13
- RUOKEQAAGRXIBM-UHFFFAOYSA-N n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(NCC#C)CCC2=C1 RUOKEQAAGRXIBM-UHFFFAOYSA-N 0.000 abstract description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 80
- 229960003638 dopamine Drugs 0.000 description 40
- JDBJJCWRXSVHOQ-UTONKHPSSA-N methanesulfonic acid;(1r)-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound CS(O)(=O)=O.C1=CC=C2[C@H](NCC#C)CCC2=C1 JDBJJCWRXSVHOQ-UTONKHPSSA-N 0.000 description 37
- XJEVHMGJSYVQBQ-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(N)CCC2=C1 XJEVHMGJSYVQBQ-UHFFFAOYSA-N 0.000 description 36
- 229960001956 rasagiline mesylate Drugs 0.000 description 36
- 239000003826 tablet Substances 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 32
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical class NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 239000000243 solution Substances 0.000 description 29
- 102000010909 Monoamine Oxidase Human genes 0.000 description 24
- 108010062431 Monoamine oxidase Proteins 0.000 description 24
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000000725 suspension Substances 0.000 description 16
- 239000012530 fluid Substances 0.000 description 15
- 208000014674 injury Diseases 0.000 description 15
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 15
- 239000007853 buffer solution Substances 0.000 description 14
- 230000002354 daily effect Effects 0.000 description 14
- 229960003946 selegiline Drugs 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 12
- 239000002207 metabolite Substances 0.000 description 12
- 230000000324 neuroprotective effect Effects 0.000 description 12
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000013270 controlled release Methods 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 10
- 210000001072 colon Anatomy 0.000 description 9
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 230000000112 colonic effect Effects 0.000 description 8
- 239000002346 layers by function Substances 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 7
- 229940025084 amphetamine Drugs 0.000 description 7
- 239000000939 antiparkinson agent Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000007884 disintegrant Substances 0.000 description 7
- 230000003291 dopaminomimetic effect Effects 0.000 description 7
- 230000002183 duodenal effect Effects 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 229960003089 pramipexole Drugs 0.000 description 7
- 101710138657 Neurotoxin Proteins 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 230000002424 anti-apoptotic effect Effects 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 230000004112 neuroprotection Effects 0.000 description 6
- 239000002581 neurotoxin Substances 0.000 description 6
- 231100000618 neurotoxin Toxicity 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 229940069328 povidone Drugs 0.000 description 6
- 229940032147 starch Drugs 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- RKMGOUZXGHZLBJ-SSDOTTSWSA-N (R)-N-Methylsalsolinol Chemical compound OC1=C(O)C=C2[C@@H](C)N(C)CCC2=C1 RKMGOUZXGHZLBJ-SSDOTTSWSA-N 0.000 description 5
- 102000003914 Cholinesterases Human genes 0.000 description 5
- 108090000322 Cholinesterases Proteins 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229940035678 anti-parkinson drug Drugs 0.000 description 5
- 229920002988 biodegradable polymer Polymers 0.000 description 5
- 239000004621 biodegradable polymer Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940048961 cholinesterase Drugs 0.000 description 5
- 210000001198 duodenum Anatomy 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000003204 osmotic effect Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 description 4
- 229920003080 Povidone K 25 Polymers 0.000 description 4
- 240000006365 Vitis vinifera Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000004245 medial forebrain bundle Anatomy 0.000 description 4
- 229940053128 nerve growth factor Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229940117803 phenethylamine Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000541 pulsatile effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007916 tablet composition Substances 0.000 description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 3
- FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- LHXOCOHMBFOVJS-OAHLLOKOSA-N Ladostigil Chemical compound CCN(C)C(=O)OC1=CC=C2CC[C@@H](NCC#C)C2=C1 LHXOCOHMBFOVJS-OAHLLOKOSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Natural products NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000648 anti-parkinson Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000005064 dopaminergic neuron Anatomy 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- VNEMYKBWMWWZIU-LLVKDONJSA-N (2r)-n-methyl-n-prop-2-ynylheptan-2-amine Chemical compound CCCCC[C@@H](C)N(C)CC#C VNEMYKBWMWWZIU-LLVKDONJSA-N 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- SJGUUGICXKISGE-UHFFFAOYSA-N 6-fluoro-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical class FC1=CC=C2CCC(NCC#C)C2=C1 SJGUUGICXKISGE-UHFFFAOYSA-N 0.000 description 2
- 208000017275 ACTH-dependent Cushing syndrome Diseases 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- QLMMOGWZCFQAPU-UHFFFAOYSA-N CGP-3466 Chemical compound C#CCN(C)CC1=CC2=CC=CC=C2OC2=CC=CC=C12 QLMMOGWZCFQAPU-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920003153 Eudragit® NE polymer Polymers 0.000 description 2
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 2
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 2
- 229920003137 Eudragit® S polymer Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- UUFAJPMQSFXDFR-LLVKDONJSA-N Norselegiline Chemical compound C#CCN[C@H](C)CC1=CC=CC=C1 UUFAJPMQSFXDFR-LLVKDONJSA-N 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- 229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical class [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 230000003942 amyloidogenic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 229940049654 glyceryl behenate Drugs 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- VNEMYKBWMWWZIU-UHFFFAOYSA-N n-methyl-n-prop-2-ynylheptan-2-amine Chemical compound CCCCCC(C)N(C)CC#C VNEMYKBWMWWZIU-UHFFFAOYSA-N 0.000 description 2
- 239000004081 narcotic agent Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 208000018360 neuromuscular disease Diseases 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 239000011236 particulate material Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000037050 permeability transition Effects 0.000 description 2
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 208000013207 pituitary-dependent Cushing disease Diseases 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000003368 psychostimulant agent Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 229960004136 rivastigmine Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940080313 sodium starch Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 239000012929 tonicity agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000031836 visual learning Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- XJEVHMGJSYVQBQ-SECBINFHSA-N (1r)-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2[C@H](N)CCC2=C1 XJEVHMGJSYVQBQ-SECBINFHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- REMZONJIIBEOHN-UHFFFAOYSA-N 4-fluoro-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound FC1=CC=CC2=C1CCC2NCC#C REMZONJIIBEOHN-UHFFFAOYSA-N 0.000 description 1
- RAWRWXXSRQSLRX-UHFFFAOYSA-N 5-fluoro-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound FC1=CC=C2C(NCC#C)CCC2=C1 RAWRWXXSRQSLRX-UHFFFAOYSA-N 0.000 description 1
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical compound O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 229940124810 Alzheimer's drug Drugs 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 206010048650 Cholinesterase inhibition Diseases 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016100 Faeces discoloured Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229940086616 Monoamine oxidase B inhibitor Drugs 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 208000034615 apoptosis-related disease Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229940031774 azilect Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- BTFHLQRNAMSNLC-UHFFFAOYSA-N clorgyline Chemical compound C#CCN(C)CCCOC1=CC=C(Cl)C=C1Cl BTFHLQRNAMSNLC-UHFFFAOYSA-N 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 208000014698 dopaminergic neuroblastoma Diseases 0.000 description 1
- 230000004771 dopaminergic neurodegeneration Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000002355 dual-layer Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 108010014977 glycine cleavage system Proteins 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229950008812 ladostigil Drugs 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- FKDHHVKWGRFRTG-UHFFFAOYSA-N linsidomine Chemical compound [N-]1OC(=N)C=[N+]1N1CCOCC1 FKDHHVKWGRFRTG-UHFFFAOYSA-N 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000013563 matrix tablet Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000001730 monoaminergic effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- UQNKNMRWWXHHFX-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-1-yl)hydroxylamine Chemical compound C1=CC=C2C(NO)CCC2=C1 UQNKNMRWWXHHFX-UHFFFAOYSA-N 0.000 description 1
- LDYSJQKNEXGCPH-UHFFFAOYSA-N n-(2-phenylethyl)prop-2-yn-1-amine Chemical class C#CCNCCC1=CC=CC=C1 LDYSJQKNEXGCPH-UHFFFAOYSA-N 0.000 description 1
- NJBSAFGMLJQVNT-UHFFFAOYSA-N n-methyl-n-prop-2-ynylbutan-1-amine Chemical compound CCCCN(C)CC#C NJBSAFGMLJQVNT-UHFFFAOYSA-N 0.000 description 1
- CJRQAPHWCGEATR-UHFFFAOYSA-N n-methyl-n-prop-2-ynylbutan-2-amine Chemical compound CCC(C)N(C)CC#C CJRQAPHWCGEATR-UHFFFAOYSA-N 0.000 description 1
- SYTFCSLHNXBWJU-UHFFFAOYSA-N n-methyl-n-prop-2-ynyldecan-2-amine Chemical compound CCCCCCCCC(C)N(C)CC#C SYTFCSLHNXBWJU-UHFFFAOYSA-N 0.000 description 1
- VAFDRBJZVFFWNL-UHFFFAOYSA-N n-methyl-n-prop-2-ynyldodecan-2-amine Chemical compound CCCCCCCCCCC(C)N(C)CC#C VAFDRBJZVFFWNL-UHFFFAOYSA-N 0.000 description 1
- OPNHJZDMXLCVAV-UHFFFAOYSA-N n-methyl-n-prop-2-ynylhexan-2-amine Chemical compound CCCCC(C)N(C)CC#C OPNHJZDMXLCVAV-UHFFFAOYSA-N 0.000 description 1
- ZLSSWZIIDZZNDQ-UHFFFAOYSA-N n-methyl-n-prop-2-ynylpentan-1-amine Chemical compound CCCCCN(C)CC#C ZLSSWZIIDZZNDQ-UHFFFAOYSA-N 0.000 description 1
- BSNWMBHBPLPDNI-UHFFFAOYSA-N n-methyl-n-prop-2-ynylpentan-2-amine Chemical compound CCCC(C)N(C)CC#C BSNWMBHBPLPDNI-UHFFFAOYSA-N 0.000 description 1
- KAKOSJKZQFWHRT-UHFFFAOYSA-N n-prop-2-ynyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C1=CC=C2C(NCC#C)CCCC2=C1 KAKOSJKZQFWHRT-UHFFFAOYSA-N 0.000 description 1
- MMUSQLTVJWLCEI-UHFFFAOYSA-N n-prop-2-ynylbutan-2-amine Chemical compound CCC(C)NCC#C MMUSQLTVJWLCEI-UHFFFAOYSA-N 0.000 description 1
- RHQTYPIWELTMCE-UHFFFAOYSA-N n-prop-2-ynyldecan-1-amine Chemical compound CCCCCCCCCCNCC#C RHQTYPIWELTMCE-UHFFFAOYSA-N 0.000 description 1
- UZYDJMMHVXJTCF-UHFFFAOYSA-N n-prop-2-ynyldecan-2-amine Chemical compound CCCCCCCCC(C)NCC#C UZYDJMMHVXJTCF-UHFFFAOYSA-N 0.000 description 1
- FBSFXULFAIHOSG-UHFFFAOYSA-N n-prop-2-ynyldodecan-1-amine Chemical compound CCCCCCCCCCCCNCC#C FBSFXULFAIHOSG-UHFFFAOYSA-N 0.000 description 1
- XGTXZOAAIYYBET-UHFFFAOYSA-N n-prop-2-ynyldodecan-2-amine Chemical compound CCCCCCCCCCC(C)NCC#C XGTXZOAAIYYBET-UHFFFAOYSA-N 0.000 description 1
- YCSAIWCJDFBKIN-UHFFFAOYSA-N n-prop-2-ynylheptan-1-amine Chemical compound CCCCCCCNCC#C YCSAIWCJDFBKIN-UHFFFAOYSA-N 0.000 description 1
- AGQBAKDLUADXOF-UHFFFAOYSA-N n-prop-2-ynylheptan-2-amine Chemical compound CCCCCC(C)NCC#C AGQBAKDLUADXOF-UHFFFAOYSA-N 0.000 description 1
- UTRPGDMUSLMURV-UHFFFAOYSA-N n-prop-2-ynylhexan-2-amine Chemical compound CCCCC(C)NCC#C UTRPGDMUSLMURV-UHFFFAOYSA-N 0.000 description 1
- ZXTHBNFMIXFSCQ-UHFFFAOYSA-N n-prop-2-ynylnonan-1-amine Chemical compound CCCCCCCCCNCC#C ZXTHBNFMIXFSCQ-UHFFFAOYSA-N 0.000 description 1
- ZMZHQPAMDCVPOZ-UHFFFAOYSA-N n-prop-2-ynylnonan-2-amine Chemical compound CCCCCCCC(C)NCC#C ZMZHQPAMDCVPOZ-UHFFFAOYSA-N 0.000 description 1
- XBOIFYIOEHOMBU-UHFFFAOYSA-N n-prop-2-ynyloctan-1-amine Chemical compound CCCCCCCCNCC#C XBOIFYIOEHOMBU-UHFFFAOYSA-N 0.000 description 1
- GXWAOZIOMOIIEV-UHFFFAOYSA-N n-prop-2-ynyloctan-2-amine Chemical compound CCCCCCC(C)NCC#C GXWAOZIOMOIIEV-UHFFFAOYSA-N 0.000 description 1
- AAUVMOAJOZSPSH-UHFFFAOYSA-N n-prop-2-ynylpentan-2-amine Chemical compound CCCC(C)NCC#C AAUVMOAJOZSPSH-UHFFFAOYSA-N 0.000 description 1
- DIGMSBSSHDJTID-UHFFFAOYSA-N n-prop-2-ynylundecan-1-amine Chemical compound CCCCCCCCCCCNCC#C DIGMSBSSHDJTID-UHFFFAOYSA-N 0.000 description 1
- HYOONJMZFULRAW-UHFFFAOYSA-N n-prop-2-ynylundecan-2-amine Chemical compound CCCCCCCCCC(C)NCC#C HYOONJMZFULRAW-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007512 neuronal protection Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- VNAXXPBYEKLMMP-UHFFFAOYSA-N o-[(3-amino-2,3-dihydro-1h-inden-5-yl)] n,n-dimethylcarbamothioate Chemical compound CN(C)C(=S)OC1=CC=C2CCC(N)C2=C1 VNAXXPBYEKLMMP-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000120 polyethyl acrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000013047 polymeric layer Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 108010005709 protein kinase C kinase Proteins 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000026843 stiff neck Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30101910P | 2010-02-03 | 2010-02-03 | |
| US61/301,019 | 2010-02-03 | ||
| PCT/IL2011/000126 WO2011095973A1 (en) | 2010-02-03 | 2011-02-03 | Extended release formulations of rasagiline and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112012019374A2 BR112012019374A2 (pt) | 2016-05-03 |
| BR112012019374B1 true BR112012019374B1 (pt) | 2022-01-11 |
Family
ID=43896855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012019374-0A BR112012019374B1 (pt) | 2010-02-03 | 2011-02-03 | Composição farmacêutica oral e uso de um agente ativo para a preparação de uma composição farmacêutica oral para o tratamento de doenças neurodegenerativas |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9943489B2 (enExample) |
| EP (2) | EP3517103A1 (enExample) |
| JP (3) | JP6045347B2 (enExample) |
| KR (1) | KR101791715B1 (enExample) |
| CN (1) | CN102791258B (enExample) |
| AU (1) | AU2011212068B2 (enExample) |
| BR (1) | BR112012019374B1 (enExample) |
| CA (1) | CA2789006C (enExample) |
| CL (1) | CL2012002175A1 (enExample) |
| CY (1) | CY1121781T1 (enExample) |
| DK (1) | DK2531181T3 (enExample) |
| ES (1) | ES2733133T3 (enExample) |
| HU (1) | HUE044221T2 (enExample) |
| IL (1) | IL221274A (enExample) |
| LT (1) | LT2531181T (enExample) |
| MX (1) | MX354423B (enExample) |
| NZ (1) | NZ602111A (enExample) |
| PL (1) | PL2531181T3 (enExample) |
| PT (1) | PT2531181T (enExample) |
| RS (1) | RS58988B1 (enExample) |
| RU (2) | RU2734632C2 (enExample) |
| SG (1) | SG183150A1 (enExample) |
| TR (1) | TR201909277T4 (enExample) |
| WO (1) | WO2011095973A1 (enExample) |
| ZA (1) | ZA201206462B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE044221T2 (hu) * | 2010-02-03 | 2019-10-28 | Pharma Two B Ltd | Nyújtott hatóanyagleadású razagilin készítmények és alkalmazásaik |
| CA2758556A1 (en) * | 2011-11-17 | 2013-05-17 | Pharmascience Inc. | Pharmaceutical composition of amphetamine mixed salts |
| US9504657B2 (en) * | 2012-01-12 | 2016-11-29 | Pharmatwob Ltd. | Fixed dose combination therapy of Parkinson's disease |
| CA2860952C (en) * | 2012-01-12 | 2020-09-15 | Pharma Two B Ltd. | Fixed dose combination therapy of parkinson's disease |
| CN103316026B (zh) | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
| CN102579367B (zh) * | 2012-03-23 | 2014-03-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 托吡酯缓释药物组合物、其制备方法及用途 |
| US9457008B2 (en) | 2012-03-23 | 2016-10-04 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Joint product comprising synephrine and topiramate |
| BR112015003451A2 (pt) * | 2012-08-17 | 2017-07-04 | Teva Pharma | formulação parentérica de rasagilina |
| IN2013MU01782A (enExample) * | 2013-05-20 | 2015-06-26 | Cadila Healthcare Ltd | |
| US20150275167A1 (en) * | 2014-03-28 | 2015-10-01 | Corning Incorporated | Composition and method for cell culture sustained release |
| HUE054957T2 (hu) * | 2014-09-15 | 2021-10-28 | Orphazyme As | Arimoklomol készítése |
| EP4327871B1 (en) | 2017-05-19 | 2025-09-24 | Biscayne Neurotherapeutics, Inc. | Modified release pharmaceutical compositions of huperzine |
| CN107049985B (zh) * | 2017-06-07 | 2020-06-19 | 广州帝奇医药技术有限公司 | 一种抗帕金森病药物的长效缓释制剂及其制备方法 |
| US11717501B2 (en) * | 2018-04-25 | 2023-08-08 | Neurocentria, Inc. | Magnesium threonate compositions and uses thereof |
| MX2021014705A (es) * | 2019-05-31 | 2022-04-06 | Denali Therapeutics Inc | Formulacion de liberacion modificada de un compuesto de pirimidinilamino-pirazol y metodos de tratamiento. |
| KR20210014289A (ko) | 2019-07-30 | 2021-02-09 | (주)비씨월드제약 | 라사길린을 함유하는 서방출성 미립구의 제조방법 |
| AR121619A1 (es) * | 2020-03-25 | 2022-06-22 | Inibsa Ginecologia S A | Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación |
| US20240269083A1 (en) * | 2021-05-11 | 2024-08-15 | Advicenne | Prolonged-release pharmaceutical composition for oral administration of sultiame |
| CN118680910B (zh) * | 2024-08-26 | 2024-12-03 | 山东齐都药业有限公司 | 用于缓释递送雷沙吉兰甲磺酸盐的药物组合物及其制备方法和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4415547A (en) * | 1982-06-14 | 1983-11-15 | Sterling Drug Inc. | Sustained-release pharmaceutical tablet and process for preparation thereof |
| US4861800A (en) | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
| HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| CA2039194C (en) | 1990-08-31 | 1997-01-28 | Norton W. Milgram | Uses of l-deprenyl and compositions for same |
| US5192808A (en) | 1990-08-31 | 1993-03-09 | Deprenyl Animal Health, Inc. | Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease) |
| US5225446A (en) | 1990-08-31 | 1993-07-06 | Deprenyl Animal Health, Inc. | Use of 1-deprenyl for retention of specific physiological functions |
| US5151449A (en) | 1990-08-31 | 1992-09-29 | Deprenyl Animal Health, Inc. | Use of L-deprenyl for retention of specific physiological functions |
| US5169868A (en) | 1991-03-01 | 1992-12-08 | University Of Saskatchewan | Aliphatic propargylamines as specific mao-b inhibitors |
| CA2107552C (en) | 1991-04-04 | 2001-08-28 | William G. Tatton | Use of deprenyl to maintain, prevent loss, or recover nerve cell function |
| WO1992021333A2 (en) | 1991-05-24 | 1992-12-10 | Pharmavene, Inc. | Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors |
| IL99759A (en) | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| US5242950A (en) | 1992-04-23 | 1993-09-07 | Somerset Pharmaceuticals, Inc. | Treatment of macular degeneration |
| JP2916978B2 (ja) * | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | 放出開始制御型製剤 |
| IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| US6348208B1 (en) | 1995-01-13 | 2002-02-19 | Somerset Pharmaceuticals, Inc. | Methods and pharmaceutical compositions employing desmethylselegiline |
| PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| EP0966435B1 (en) | 1996-12-18 | 2005-04-06 | Teva Pharmaceutical Industries, Ltd. | Aminoindan derivatives |
| US6251938B1 (en) | 1996-12-18 | 2001-06-26 | Teva Pharmaceutical Industries, Ltd., | Phenylethylamine derivatives |
| US5840979A (en) | 1997-07-14 | 1998-11-24 | University Of Saskatchewan | Aliphatic propargylamines as cellular rescue agents |
| KR20020008167A (ko) | 1999-04-29 | 2002-01-29 | 플레믹 크리스티안 | 잠재적 항정신병제로서의 글리신 분해계 저해제 |
| AU2002355686B2 (en) * | 2001-07-04 | 2007-11-29 | Sun Pharmaceutical Industries Limited | Gastric retention controlled drug delivery system |
| US20040076668A1 (en) | 2002-07-03 | 2004-04-22 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
| SI1567152T1 (sl) * | 2002-11-15 | 2013-10-30 | Teva Pharmaceutical Industries Ltd. | Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze |
| KR20060124731A (ko) * | 2004-01-29 | 2006-12-05 | 뉴로몰레큘라 파마슈티칼스, 인코포레이티드 | 중추신경계-관련 질환 치료용 ｎｍｄａ 수용체 길항제 및ｍａｏ-억제제 또는 ｇａｄｐｈ-억제제의 배합물 |
| CA2574925A1 (en) * | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical dosage forms including rasagiline |
| MX2008000084A (es) * | 2005-06-29 | 2008-03-18 | Panacea Biotec Ltd | Composiciones farmaceuticas de liberacion sostenida y procedimientos de las mismas. |
| NZ565649A (en) * | 2005-07-28 | 2011-03-31 | Shire Llc | Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily |
| JP2009502957A (ja) * | 2005-07-28 | 2009-01-29 | スパーナス ファーマシューティカルズ インコーポレイテッド | 機械的特性の向上した徐放性錠剤配合物 |
| CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| CN101486655A (zh) | 2008-01-17 | 2009-07-22 | 美德（江西）生物科技有限公司 | 甲磺酸雷沙吉兰晶形及其制备方法 |
| WO2009147681A1 (en) | 2008-06-06 | 2009-12-10 | Pharma Two B Ltd. | Pharmaceutical compositions for treatment of parkinson's disease |
| US20100008983A1 (en) | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
| WO2010007181A2 (en) * | 2008-07-18 | 2010-01-21 | Medichem, S.A. | New salt forms of an aminoindan derivative |
| EP2218444A3 (en) | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| HUE044221T2 (hu) * | 2010-02-03 | 2019-10-28 | Pharma Two B Ltd | Nyújtott hatóanyagleadású razagilin készítmények és alkalmazásaik |
-
2011
- 2011-02-03 HU HUE11707489 patent/HUE044221T2/hu unknown
- 2011-02-03 BR BR112012019374-0A patent/BR112012019374B1/pt active IP Right Grant
- 2011-02-03 RU RU2016141314A patent/RU2734632C2/ru active
- 2011-02-03 PL PL11707489T patent/PL2531181T3/pl unknown
- 2011-02-03 RU RU2012136723A patent/RU2607595C2/ru active
- 2011-02-03 KR KR1020127023006A patent/KR101791715B1/ko active Active
- 2011-02-03 DK DK11707489.8T patent/DK2531181T3/da active
- 2011-02-03 EP EP19159171.8A patent/EP3517103A1/en not_active Withdrawn
- 2011-02-03 CN CN201180012590.4A patent/CN102791258B/zh active Active
- 2011-02-03 NZ NZ602111A patent/NZ602111A/en not_active IP Right Cessation
- 2011-02-03 CA CA2789006A patent/CA2789006C/en active Active
- 2011-02-03 LT LTEP11707489.8T patent/LT2531181T/lt unknown
- 2011-02-03 WO PCT/IL2011/000126 patent/WO2011095973A1/en not_active Ceased
- 2011-02-03 ES ES11707489T patent/ES2733133T3/es active Active
- 2011-02-03 PT PT11707489T patent/PT2531181T/pt unknown
- 2011-02-03 RS RS20190810A patent/RS58988B1/sr unknown
- 2011-02-03 TR TR2019/09277T patent/TR201909277T4/tr unknown
- 2011-02-03 EP EP11707489.8A patent/EP2531181B1/en active Active
- 2011-02-03 AU AU2011212068A patent/AU2011212068B2/en active Active
- 2011-02-03 SG SG2012057493A patent/SG183150A1/en unknown
- 2011-02-03 US US13/577,099 patent/US9943489B2/en active Active
- 2011-02-03 MX MX2012009079A patent/MX354423B/es active IP Right Grant
- 2011-02-03 JP JP2012551732A patent/JP6045347B2/ja active Active
-
2012
- 2012-08-02 IL IL221274A patent/IL221274A/en active IP Right Grant
- 2012-08-03 CL CL2012002175A patent/CL2012002175A1/es unknown
- 2012-08-28 ZA ZA2012/06462A patent/ZA201206462B/en unknown
-
2016
- 2016-09-26 JP JP2016186945A patent/JP6440662B2/ja active Active
-
2018
- 2018-11-20 JP JP2018216973A patent/JP6770564B2/ja active Active
-
2019
- 2019-07-03 CY CY20191100699T patent/CY1121781T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2789006C (en) | Extended release formulations of rasagiline and uses thereof | |
| AU2018202002B2 (en) | Methods and compositions for treatment of attention deficit disorder | |
| JP2005506367A (ja) | 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬 | |
| EP2802319B1 (en) | Fixed dose combination therapy of parkinson's disease | |
| US7235258B1 (en) | Sustained-release formulations for treating CNS-mediated disorders | |
| HK40073671B (en) | Methods and compositions for treatment of attention deficit disorder | |
| HK40107582A (en) | Methods and compositions for treatment of attention deficit disorder | |
| HK1203847B (en) | Fixed dose combination therapy of parkinson's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/02/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |